Charles River Laboratories, Inc. to launch a new service, AccuPedia. This is referred to as a new informational database that provides a deeper and enhanced look into microorganisms. AccuPedia also assists healthcare providers to make confident operational decisions based on the characteristics of microflora.
Texcell Inc. to organize the Viral Safety Days series for the first time. The company is hosting three national events for scientific discussion, networking, presentation, and others. Topics such as, purification to regulatory, therapeutics, and antibodies for gene therapies will be included.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3939
Published Date: Feb 15, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing cases of chronic disease and a significant increment in the number of viral fevers are estimated to majorly boost market growth.
The market is anticipated to attain a CAGR of 20% over the forecast period, i.e., 2023-2033.
Long-lasting development procedure for drug discovery and the lack of the requisite medical workforce is estimated to challenge the market growth.
The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.
The major players in the market are Texcell Inc., Merck KGaA, Charles River Laboratories, Inc., Sartorius AG, SGS AG, Syngene International Limited, Lonza AG, Kedrion S. p. A., and others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.
The market is segmented by method, application, end-user, and by region.
The CROs segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.